Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de Botensilimab y Balstilimab para el cáncer colorrectal

21 de septiembre de 2026 actualizado por: Memorial Sloan Kettering Cancer Center

Estudio de fase II del adyuvante botensilimab en combinación con balstilimab en pacientes con cáncer colorrectal y ADN tumoral circulante persistente tras cirugía y quimioterapia

The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal cancer or colorectal liver metastases (CRLM) who have measurable residual disease (MRD) after standard treatment with surgery and chemotherapy or total neoadjuvant therapy (TNT).

Descripción general del estudio

Estado

Reclutamiento

Descripción detallada

This is a 2-part, 2-cohort each. Part-1 will be a non-randomized study of 54 subjects to assess ctDNA clearance, including 2 cohorts. Cohort 1a includes 27 patients with stage III non-MSI-H/pMMR colorectal cancer following surgery and adjuvant chemotherapy or total neoadjuvant therapy (TNT), with persistent MRD. Cohort 1b includes 27 patients with non-MSI-H/pMMR CRLM following surgery and peri-operative chemotherapy, with persistent MRD.

Part-2 will be a randomized, placebo-controlled, double-blind study of 230 patients with non- MSI-H/pMMR CRC with MRD, to assess RFS. Cohort 2a includes 113 patients with stage III non-MSI-H/pMMR colorectal cancer following surgery and adjuvant chemotherapy or TNT with persistent MRD, randomized 2:1 to treatment versus placebo.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

284

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Luis Diaz, MD
  • Número de teléfono: 646-888-4641

Copia de seguridad de contactos de estudio

  • Nombre: Neil Segal, MD, PhD
  • Número de teléfono: 646-888-4187
  • Correo electrónico: crc@mskcc.org

Ubicaciones de estudio

    • New Jersey
      • Basking Ridge, New Jersey, Estados Unidos, 07920
        • Reclutamiento
        • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
        • Contacto:
          • Neil Segal, MD, PhD
          • Número de teléfono: 646-888-4187
      • Middletown, New Jersey, Estados Unidos, 07748
        • Reclutamiento
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • Contacto:
          • Neil Segal, MD, PhD
          • Número de teléfono: 646-888-4187
      • Montvale, New Jersey, Estados Unidos, 07645
        • Reclutamiento
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • Contacto:
          • Neil Segal, MD, PhD
          • Número de teléfono: 646-888-4187
    • New York
      • Commack, New York, Estados Unidos, 11725
        • Reclutamiento
        • Memorial Sloan Kettering Commack (Limited Protocol Activities)
        • Contacto:
          • Neil Segal, MD, PhD
          • Número de teléfono: 646-888-4187
      • Harrison, New York, Estados Unidos, 10604
        • Reclutamiento
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
        • Contacto:
          • Neil Segal, MD, PhD
          • Número de teléfono: 646-888-4187
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
        • Contacto:
          • Luis Diaz, MD
          • Número de teléfono: 646-888-4641
        • Contacto:
          • Neil Segal, MD,PhD
          • Número de teléfono: 646-888-4187
        • Investigador principal:
          • Neil Segal, MD, PhD
      • Rockville Centre, New York, Estados Unidos, 11553
        • Reclutamiento
        • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
        • Contacto:
          • Neil Segal, MD, PhD
          • Número de teléfono: 646-888-4187

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Subject or legally authorized representative, is willing and able to provide written informed consent.

  • Histologically- or cytologically- confirmed colorectal cancer.

  • ≥ 18 years of age on day of signing informed consent.

  • Consent for use of archival tissue and blood draws for research purposes.

  • Performance status of ECOG 0 or 1.

  • Known non-MSI-H/pMMR by IHC, PCR or NGS testing. MSKCC confirmation of non-MSI-H/pMMR status is not mandatory prior to enrollment and treatment on the study. For patients with outside testing, if sufficient tissue is available testing may be repeated at MSKCC and will not impact initial eligibility.

  • Consent to undergo MSK IMPACT or NGS, if not previously done

  • Disease specific criteria:

    1. Cohorts 1a and 2a: Undergone a complete surgical resection (R0) for stage III colon or rectal cancer, followed by adjuvant chemotherapy with FOLFOX or CAPEOX. Post-operative chemotherapy not required if received previous oxaliplatin-based therapy. Total Neoadjuvant Therapy for rectal cancer with complete clinical and radiographic response is allowed.
    2. Cohorts 1b and 2b: Undergone a complete surgical resection (R0) for liver metastasis (ablation or stereotactic body radiation therapy [SBRT], but not Y-90, is permitted) and completed standard peri-operative chemotherapy. Peri-operative chemotherapy not required if received previous oxaliplatin-based therapy. Prior floxuridine via Hepatic Arterial Infusion Pump is permitted. Completed definitive treatment for the primary tumor including (R0) resection, or Total Neoadjuvant Therapy for rectal cancer with complete clinical and radiographic response.
  • Positive ctDNA following completion of appropriate standard of care therapy.

  • Patients must sign informed consent within 6 weeks of positive ctDNA result. The 6 weeks is considered from the date that the ctDNA is resulted, and not the date it is drawn.

Adequate organ function, defined as:

  1. Absolute Neutrophil Count ≥ 1,500/mm3.

  2. Platelet count ≥ 75,000/mm3.

  3. Hemoglobin ≥ 9.0 g/dL

  4. Creatinine clearance (CrCl) ≥60 mL/min.

  5. AST and ALT ≤ 2.5 × ULN

  6. Bilirubin ≤ 1.5 × ULN or Direct bilirubin ≤ ULN

    • Subjects of childbearing potential (or with partners of childbearing potential) must use effective contraception for the course of the study starting with the screening visit through at least 5 months after the last dose of study treatment. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives, or double barrier method (diaphragm plus condom).

Exclusion Criteria:

  • Presence of metastatic or recurrent disease.

  • Known DNA polymerase epsilon (POLE) or DNA polymerase delta (POLD) activating mutation.

  • R1 (microscopic residual tumor) or R2 resection (macroscopic residual tumor at resection margin).

  • Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

  • Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

    1. Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone containing antiemetic regimen or steroids as CT scan contrast premedication) may be enrolled.
    2. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
  • Hypersensitivity to botensilimab or balstilimab or any of its excipients.

  • Chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent

    a. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

  • History of, or any evidence of active, non-infectious pneumonitis.

  • Active infection requiring systemic therapy.

  • Current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

  • Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 90 days after the last dose of trial treatment.

  • Prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent.

  • Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (i.e., with use of disease-modifying agents or immunosuppressive drugs). The following are exceptions:

    1. Subjects with vitiligo or alopecia
    2. Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment
  • Known active TB (Bacillus tuberculosis).

  • Uncontrolled infection with human immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required

  • Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Patients who are receiving or who have received anti-HBV therapy and have undetectable HBV DNA prior to study entry are eligible. Serological testing for HBV at screening is not required.

  • Known active hepatitis C virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Patients on or who have received antiretroviral therapy are eligible provided they are virus-free by PCR for at least 6 months prior to study entry. Serological testing for HCV at screening is not required.

  • Received a live vaccine within 30 days of planned start of study therapy

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Cohort 1a: Stage III MSS Colorectal Cancer (Botensilimab and Balstilimab)

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses, balstilimab IV on days 1, 15, and 29 of the 42 day cycle. Patient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses

Otros nombres:
  • AGEN1181

All patients will receive balstilimab IV on days 1, 15, and 29 of the 42 day cyclePatient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

Otros nombres:
  • AGEN2034
Experimental: Cohort 1b: MSS CRLM (Botensilimab and Balstilimab)

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses, balstilimab IV on days 1, 15, and 29 of the 42 day cycle. Patient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses

Otros nombres:
  • AGEN1181

All patients will receive balstilimab IV on days 1, 15, and 29 of the 42 day cyclePatient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

Otros nombres:
  • AGEN2034
Experimental: Cohort 2a: Stage 3 MSS Colorectal Cancer (Botensilimab and Balstilimab vs. Placebo) Randomized

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses, balstilimab IV on days 1, 15, and 29 of the 42 day cycle. Patient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle OR Placebo

Placebo

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses

Otros nombres:
  • AGEN1181

All patients will receive balstilimab IV on days 1, 15, and 29 of the 42 day cyclePatient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

Otros nombres:
  • AGEN2034
Experimental: Cohort 2b: MSS CRLM (Botensilimab and Balstilimab vs. Placebo) Randomized

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses, balstilimab IV on days 1, 15, and 29 of the 42 day cycle. Patient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle OR Placebo

Placebo

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses

Otros nombres:
  • AGEN1181

All patients will receive balstilimab IV on days 1, 15, and 29 of the 42 day cyclePatient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

Otros nombres:
  • AGEN2034

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Supervivencia libre de recurrencia (SLR) (Cohorte 2a)
Periodo de tiempo: 1 año
1 año
Supervivencia libre de recurrencia (SLR) (Cohorte 2b)
Periodo de tiempo: 1 año
1 año
Rate of ctDNA clearance (Cohort 1a)
Periodo de tiempo: 6 months

The 6 months ctDNA clearance will be estimated using the binomial distribution along with exact 95% confidence intervals separately in each cohort.

6 months
Rate of ctDNA clearance (Cohort 1b)
Periodo de tiempo: 6 months

The 6 months ctDNA clearance will be estimated using the binomial distribution along with exact 95% confidence intervals separately in each cohort.

6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Investigador principal: Neil Segal, MD, PhD, Memorial Sloan Kettering Cancer Center

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

7 de noviembre de 2025

Finalización primaria (Estimado)

1 de noviembre de 2030

Finalización del estudio (Estimado)

1 de noviembre de 2030

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2025

Publicado por primera vez (Actual)

13 de noviembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir